Default company panoramic image
Bf726302 e87f 4218 b28b bb3a4d881b96

(S) Etifoxine Development Fund, LLC

SEDF funding the FDA approval process for a uniquely low risk, non-opiate, non-addictive, non-sedating, pain drug without GI side effects.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Metairie, LA, USA
  • Currency USD
  • Founded May 2012
  • Employees 0
  • Website ng-dg.com

Company Summary

SEDF was formed by a group of pharmaceutical industry veterans to develop (S)Etifoxine, an active component of an existing, clinically proven safe and effective drug as a novel, first-in-class pain treatment. Our management team and Strategic Advisory Board have extensive experience developing drugs with numerous large and medium sized pharmaceutical companies. (S)Etifoxine should make a significant difference in the way we treat pain.

Team

  • Default avatar
    Brent A. Kovach
    Chief Executive Officer

  • Default avatar
    Steven K. Duddy, Ph.D.
    Chief Scientific Officer

  • Default avatar
    Layne E. Los, Ph.D.
    Chief Operating Officer

Advisors

  • Default avatar
    Charles Berry
    Lawyer
    Unconfirmed
    Default avatar
    Craig Silva
    Accountant
    Unconfirmed